Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

#	Biosimilar	Applicant	Reference Product	aBLA Approval	US Launch?	Pending BPCIA Litigation?
1	ZARXIO® (filgrastim-sndz)	Sandoz	NEUPOGEN®	Mar. 6, 2015	Sept. 3, 2015	Amgen v. Sandoz
2	INFLECTRA® (infliximab-dyyb)	Celltrion	REMICADE®	Apr. 5, 2016	Late 2016	Janssen v. Celltrion
3	ERELZI® (etanercept-szzs)	Sandoz	ENBREL®	Aug. 30, 2016	No	Immunex v. Sandoz
4	AMJEVITA® (adalimumab-atto)	Amgen	HUMIRA®	Sept. 23, 2016	No	AbbVie v. Amgen
5	RENFLEXIS® (infliximab-abda)	Samsung Bioepis	REMICADE®	Apr. 21, 2017	No	None

FDA-Approved aBLAs

Related Content

Genentech and Dr. Reddy’s Settle BPCIA Rituximab Litigation

MDL Panel Grants Transfer of Aflibercept BPCIA Case

FDA Approves BMS and J&J CAR-T Cell Therapies for the Earlier Treatment of Multiple Myeloma

FDA Approves New Indication for AstraZeneca and Daiichi Sankyo’s Cancer Drug ENHERTU

REGENXBIO and Sarepta Agree to Stay Litigation Pending Outcome of Sarepta’s IPR Petition

Fresenius Kabi and Formycon Reach Settlement Agreement for Ustekinumab Biosimilar Candidate in Europe and Canada

FDA Approves First Gene Therapy to Treat Children with Metachromatic Leukodystrophy

Biden Administration Proposes Biosimilar Substitution Without Interchangeability

Goodwin Named an LMG Life Sciences Life Cycle Firm for the Twelfth Consecutive Year

LMG Recognizes Goodwin Lawyers and Practices for Excellence in Life Sciences

Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.

Goodwin Named an LMG Life Sciences Life Cycle Firm for the Tenth Consecutive Year

Goodwin Adds Life Sciences and Healthcare Litigation Partner William Jackson

China's Patent Linkage System: Can Strategies that Work in the U.S. System Be Applied to China?

Goodwin Named An LMG Life Sciences Life Cycle Firm For The Ninth Consecutive Year

ACI's 11th Summit on Biosimilars & Innovator Biologics

Life Sciences

Hatch-Waxman, Biologics and Biosimilars Litigation